




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61K 31/65		A1	(11) International Publication Number: WO 00/07601
			(43) International Publication Date: 17 February 2000 (17.02.00)
(21) International Application Number: PCT/US99/17185 (22) International Filing Date: 29 July 1999 (29.07.99) (30) Priority Data: 09/130,638 6 August 1998 (06.08.98) US (71) Applicant: ADVANCED VISION RESEARCH [US/US]; Suite 330, 7 Alfred Street, Woburn, MA 01801 (US). (72) Inventor: GILBARD, Jeffrey, P.; 48 Ridgeway Road, Weston, MA 02493 (US). (74) Agents: LOREN, Ralph, A. et al.; Lahive & Cockfield, LLP, 28 State Street, Boston, MA 02109 (US).		(81) Designated States: AU, BR, CA, JP, MX, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	

(54) Title: OPHTHALMIC SOLUTION WITH TETRACYCLINE FOR TOPICAL TREATMENT OF DRY EYE DISEASE

EFFECT OF VARIOUS TETRACYCLINE TREATMENTS ON CONJUNCTIVAL
GOBLET-CELL DENSITY IN A RABBIT MODEL FOR MEIBOMITIS/
MEIBOMIAN GLAND DYSFUNCTION



(57) Abstract

Ophthalmic compositions and methods of using the same to simultaneously treat eye surface inflammation and dry eye are disclosed. The ophthalmic preparation contains a tetracycline compound in aqueous solution. The preparation preferably further includes a balance of electrolytes sufficient to maintain or restore essentially normal levels of conjunctival mucus-containing goblet cells and corneal glycogen. These electrolytes can include potassium, chloride, bicarbonate, sodium, calcium, magnesium and phosphate.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

OPHTHALMIC SOLUTION WITH TETRACYCLINE FOR TOPICAL TREATMENT OF DRY EYE DISEASE

Government Funding

5 This invention was made with government support under grant EY03373 from the National Eye Institute. The United States government has certain rights in the invention.

Background of the Invention

10 This invention relates to therapeutic ophthalmic preparations and methods of using the preparations locally to treat eye surface inflammation including meibomianitis and related dry eye disease. More particularly, it relates to topical ophthalmic solutions containing tetracycline compounds to suppress eye surface inflammation, including meibomianitis, while maintaining or restoring conjunctival mucus-containing goblet
15 cells.

 Systemic tetracyclines are currently used to treat ocular rosacea, a condition characterized by eye surface inflammation, and a variety of related eye disorders such as blepharitis, meibomianitis, keratitis, conjunctival hyperemia, and eyelid hyperemia. Open-label prospective studies have been published describing a decrease in blepharitis
20 and conjunctival hyperemia associated with ocular rosacea following systemic administration of tetracycline (1, 2). Systemic oxytetracycline treatment of ocular rosacea has also been tested in a double-masked trial and found to be more effective than placebo in inducing remissions (3). In the trial, it was reported that eyelid and conjunctival hyperemia responded well, as did the associated blepharitis.

25 Based on these studies and clinical experience, oral tetracyclines has been recommended for treating meibomianitis, blepharitis and eye surface inflammation (4, 5, 6). Meibomianitis is a disorder characterized by inflammation centered about the meibomian glands. When inflammation includes most of the eye lid, the general term "blepharitis" may be applied. When inflammation includes the conjunctiva, the term
30 "conjunctivitis" applies. When inflammation involves the cornea, the term "keratitis" applies. The eye surface includes the eye lids, cornea and conjunctiva. Recently, it was observed that meibomianitis and eye surface inflammation develops in a rabbit model for meibomian gland dysfunction (7). Analogous findings have been reported in humans (8, 9). These studies show that meibomianitis leads to meibomian gland
35 dysfunction, with loss of meibomian gland oil from the tear film, an increase in tear film evaporation, a loss of water from the tear film and the development of dry eye surface disease.

Specifically, in the aforementioned rabbit model of meibomian gland dysfunction, meibomian gland orifice closure increases tear film osmolarity and decreases corneal epithelial glycogen and conjunctival goblet-cell density. These decreases are analogous to those seen with keratoconjunctivitis sicca (commonly known as "dry eye") from lacrimal gland disease (10, 11). The clinical relevance of these data has been further supported by studies demonstrating that patients with meibomian gland drop out have significantly elevated tear film evaporative rates and tear film osmolarity (12).

Just how tetracyclines work in the treatment of ocular surface inflammatory disorders, such as ocular rosacea, meibomianitis, blepharitis, conjunctivitis and keratitis has previously been unknown. However, elsewhere in the body it has been known that tetracyclines have potent antibacterial properties, inhibit collagenase activity (15, 16, 17), and decrease leukocyte chemotaxis (18, 19, 20, 21) and phagocytosis (22). When administered systemically, tetracycline enters into the tears (13) and concentrates in goblet cells, around blood vessels, and on the external surface of the conjunctival epithelium (14). Systemic administration of tetracycline, however, has several drawbacks. For example, it often results in adverse side effects, including gastrointestinal irritation, vaginal yeast infection, sunlight sensitivity and systemic allergic reactions.

Accordingly, it is an object of this invention to provide an improved ophthalmic preparation for locally delivering a tetracycline compound to ocular surfaces. It is another object of this invention to provide an ophthalmic solution for locally delivering a tetracycline compound to ocular surfaces, while maintaining or restoring essentially normal levels of conjunctival mucus-containing goblet cells. It is a further object of this invention to provide an electrolyte-based tetracycline formulation for simultaneously treating inflammatory eye diseases, such as meibomianitis, and associated blepharitis and dry eye disorders.

Additional objects of the invention will be apparent from the following description.

30

Summary of the Invention

A therapeutic preparation for ophthalmic use has been developed that provides the advantage of drug delivery and treatment or prevention of dry eye disease. The preparation contains an anti-inflammatory agent, such as a tetracycline compound, in an electrolyte-based solution which can be applied topically to the eye, permitting the maintenance or restoration of essentially normal levels of conjunctival mucus-containing goblet cells and corneal glycogen. The ophthalmic preparation thus provides

35

the advantages of local tetracycline delivery to ocular surfaces without a substantial decrease in mucus-containing goblet cells or corneal glycogen typically associated with the use of standard ophthalmic preparations. The ophthalmic preparation provides the further advantage of increasing low goblet cell density and corneal glycogen levels
5 associated with the dry eye surface disease resulting from meibomian gland dysfunction. In contrast, standard ophthalmic preparations have been shown in studies described herein to exacerbate the loss of goblet cells and corneal glycogen.

In general, the ophthalmic preparation contains an aqueous solution of a tetracycline compound in an amount sufficient to treat an ocular disease characterized
10 by eye surface inflammation with or without dryness. The preparation preferably also includes a balance of electrolytes found in natural tear fluid required for ocular surface maintenance, function and repair. In preferred embodiments, these electrolytes are present in amounts sufficient to maintain or restore essentially normal levels of conjunctival goblet cells and corneal glycogen, thereby maintaining mucus-mediated
15 lubrication and the potential for normal healing. In a particularly preferred embodiment, the tetracycline compound is contained in Solution 15, described in U.S. Patent No. 4,911,933, the contents of which are hereby incorporated by reference.

Principal electrolytes employed in the invention include, but are not limited to, sodium and chloride, in combination with lesser amounts of potassium and bicarbonate.
20 Typically, these electrolytes are present in the following concentration ranges:

Potassium between about 22.0 to 43.0 millimoles per liter (mM/l), preferably between about 23.0 to 42.0 mM/l;

Bicarbonate between about 29.0 to 50.0 mM/l, preferably between about 31.0 to 48.0 mM/l;

25 Sodium between about 130.0 to 140.0 mM/l, preferably between about 131.0 to 139.0 mM/l; and

Chloride between about 118.0 to 136.5 mM/l, preferably between about 124.0 to 136.0 mM/l.

Additional electrolytes which can be employed in the ophthalmic preparation, in
30 combination with the above-listed electrolytes include, but are not limited to, calcium, magnesium and phosphate. Typically, these electrolytes are typically present in the following concentration ranges:

Magnesium between about 0.3 to 1.1 mM/l, preferably between about 0.5 to 0.6 mM/l,

35 Calcium between about 0.5 to 2.0 mM/l, preferably between about 0.6 to 0.8 mM/l, and

Phosphate between about 0.8 to 2.2 mM/l, preferably between about 1.8 to 2.0 mM/l.

The concentration of the tetracycline compound will vary depending on the nature and severity of the eye surface inflammation being treated and the specific tetracycline compound used. Generally, for tetracycline, the concentration in solution will range from about 0.125% to 2% when the solution is isotonic or attains isotonicity. Any suitable tetracycline compound (including tetracycline derivatives, analogs and salts thereof) known in the art can be used, such as those described in further detail below.

Ophthalmic preparations of the present invention can be used in methods of treating ocular disorders characterized by eye surface inflammation, such as meibomianitis or eye surface redness. Typically, the preparation is applied topically to the surface of the eye in an amount sufficient to treat the disorder. The ophthalmic preparation can also be used to simultaneously reduce eye surface inflammation and dryness, based on the presence of an active tetracycline compound in an aqueous solution containing the necessary balance of electrolytes for ocular surface maintenance, function and repair. The ophthalmic preparation can further maintain or restore conjunctival goblet cells and corneal glycogen which are typically depleted in dry eye disorders.

These and other embodiments of the invention will be apparent from the following detailed description and working examples.

Brief Description of the Figures

Figure 1 is a graph showing leukocyte densities in tarsal conjunctival epithelium of (left to right) (a) normal control rabbits, (b) untreated control rabbits with meibomianitis/meibomian gland dysfunction, (c) rabbits treated with tetracycline in saline (administered intramuscularly (IM)), (d) rabbits treated with tetracycline in Achromycin™ light mineral oil eyedrops (administered topically), and (e) rabbits treated with tetracycline in Solution 15 (administered topically).

Figure 2 is a graph showing leukocyte densities in conjunctival stroma of (a) normal control rabbits, (b) untreated control rabbits with meibomianitis/meibomian gland dysfunction, (c) rabbits treated with tetracycline in saline (administered intramuscularly (IM)), (d) rabbits treated with tetracycline in Achromycin™ light mineral oil eyedrops (administered topically), and (e) rabbits treated with tetracycline in Solution 15 (administered topically).

Figure 3 is a graph showing leukocyte densities in meibomian glands and tarsal plate of (a) normal control rabbits, (b) untreated control rabbits with

meibomianitis/meibomian gland dysfunction, (c) rabbits treated with tetracycline in saline (administered intramuscularly (IM)), (d) rabbits treated with tetracycline in Achromycin™ light mineral oil eyedrops (administered topically), and (e) rabbits treated with tetracycline in Solution 15 (administered topically).

5 Figure 4 is a graph showing the effect of the following tetracycline formulations on conjunctival goblet-cell density in a rabbit model for meibomianitis/meibomian gland dysfunction: (a) tetracycline in saline (administered intramuscularly (IM)), (b) tetracycline in Achromycin™ light mineral oil eyedrops (administered topically), and (c) tetracycline in Solution 15 (administered topically).

10 Figure 5 is a graph showing the effect of the following tetracycline formulations on corneal glycogen in a rabbit model for meibomianitis/meibomian gland dysfunction: (a) tetracycline in saline (administered intramuscularly (IM)), (b) tetracycline in Achromycin™ light mineral oil eyedrops (administered topically), and (c) tetracycline in Solution 15 (administered topically).

15

Detailed Description of the Invention

In accordance with the invention, a therapeutic ophthalmic preparation combines at least one tetracycline compound in an electrolyte-based aqueous solution to locally treat both eye surface inflammation and related dry eye disorders.

20 As used herein, the term "a tetracycline compound" refers to all known tetracyclines, tetracycline analogs, breakdown products, and derivatives thereof (e.g., HCL derivatives thereof). Such compounds are well known in the art, primarily for their potent anti-bacterial properties, and include, but are not limited to, methacycline, oxytetracycline, minocycline, demeclocycline, doxycycline, tetracycline, 25 chlortetracycline, and salts thereof. These tetracycline compounds are described throughout the literature, for example, in the Merck Manual (e.g., Fifteenth Ed. (1987), p.38-39), the contents of which are incorporated by reference herein. It is preferable that the tetracycline is not highly photosensitive. In this respect, tetracycline and minocycline (as well as hydrochloride derivatives thereof) are preferred (Li et al. (1987) 30 Biochem. Biophys. Res. Commun. 146:1191). From a functional standpoint, preferred tetracycline compounds for use in the invention are capable of inhibiting leukocyte chemotaxis. The aforementioned tetracycline compounds are commercially available, for example, from Sigma Chemical Corp., St. Louis, Mo.

35 In contrast to topical ointments and oil-based carriers known in the art, the tetracycline compound of the present invention is formulated in an aqueous solution, preferably containing electrolytes. Suitable concentrations of the tetracycline compound in solution include those equivalent in anti-inflammatory potency to tetracycline at a

concentration range of between about 0.125% and 2% when the solution is isotonic or attains isotonicity.

The preparation preferably also includes a balance of electrolytes found in natural tear fluid required for ocular surface maintenance, function and repair. In preferred embodiments, these electrolytes are present in amounts sufficient to maintain or restore conjunctival goblet cells and corneal glycogen, thereby maintaining mucus-mediated lubrication and the potential for normal healing. This enables topical application of the preparation to ocular surfaces preferably without substantially reducing the density of conjunctival mucus-containing goblet cells or levels of corneal glycogen. Goblet cells form a critical layer of the tear film, providing the eye surface with lubrication, and playing an important role in the system that traps foreign matter that may enter the eye, and promptly removes it. Corneal glycogen is the energy source for the sliding step in corneal wound healing. Their preservation is therefore important in maintaining the health of ocular surfaces.

As used herein, the term "eye surface inflammation" includes any inflammatory disorder involving the ocular surface. The eye surface includes the eye lids, conjunctiva and cornea. Inflammation refers to white blood cell or leukocytic infiltration associated with cellular injury. Eye surface inflammatory disorders treatable by the ophthalmic preparation of the invention are typically manifested by signs and symptoms such as eye redness, or irritation. These diseases include, for example, meibomianitis, blepharitis conjunctival hyperemia, eyelid hyperemia, keratitis and ocular rosacea.

As used herein, the term "eye surface dryness" includes any ocular disorder resulting in loss of water from the tear film. Such disorders generally can be characterized by increased tear film osmolarity and decreased levels of corneal glycogen and conjunctival mucus-containing goblet cells. Eye surface dryness can result from a number of different diseases including, for example, meibomian gland dysfunction and meibomian gland orifice stenosis or closure.

As previously described herein, eye surface inflammatory disorders are often associated with eye surface dryness and irritation. Animal models for such combined ocular disorders have been produced, and can be used to test the efficacy of the ophthalmic preparations provided herein. For example, a rabbit model for meibomianitis and meibomian gland dysfunction has been developed (7). In this animal model, meibomian gland orifice closure results in the development of inflammation around the meibomian glands (i.e., meibomianitis), inflammation in the eyelids (blepharitis), inflammation in the conjunctiva (conjunctivitis) and in an increase in tear film osmolarity and a decrease in the levels of corneal glycogen and conjunctival mucus-containing goblet cells. As demonstrated in the Examples below, ophthalmic

preparations of the invention effectively treat both the eye surface inflammation (i.e., meibomianitis) and associated eye surface dryness (elevated tear film osmolarity, decreased goblet cell density and reduced corneal glycogen) exhibited by this animal model. It is recognized that results of tests using rabbits has close correlation with humans and, therefore, that the results carry over to humans.

Ophthalmic preparations of the invention include aqueous solutions containing one or more tetracycline compounds which are, collectively, present in an amount sufficient to treat eye surface inflammation, such as meibomianitis or eye surface redness.

In preferred embodiments, ophthalmic preparations of the invention include, in addition to one or more tetracyclines, a balance of electrolytes naturally found in tear fluid. These electrolytes principally include major amounts of sodium and chloride, and lesser amounts of potassium and bicarbonate. The preparation may also contain other naturally-occurring elements of the tear fluid, such as proteins, enzymes, lipids and metabolites as described in U.S. Patent No. 4,911,933. Typically, the potassium is present at a concentration of about 22.0 to 43.0 mM/l, the bicarbonate is present at a concentration of about 29.0 to 50.0 mM/l, the sodium is present at a concentration of about 130.0 to 140.0 mM/l, and the chloride is present at a concentration of about 118.0 to 136.5 mM/l. The osmolarity of the resulting solution is preferably in the range of about 296 to 325 mOsm/Kg, but water may be added or removed from the preparation to create appropriate therapeutic dilutions or concentrations.

The ophthalmic preparation can further optionally include calcium, magnesium and phosphate. In such embodiments, the calcium is preferably present at a concentration of about 0.5 to 2.0 mM/l, the magnesium is preferably present at a concentration of about 0.3 to 1.1 mM/l, and the phosphate is preferably present at a concentration of about 0.8 to 2.2 mM/l.

Accordingly, in a particular embodiment, the invention provides an ophthalmic solution having an osmolarity of about 296-325 mOsm/Kg, which includes at least the following components: (a) tetracycline at a concentration of about 0.125% to 2%; (b) potassium at a concentration of about 22.0 to 43.0 mM/l; (c) bicarbonate at a concentration of about 29.0 to 50.0 mM/l; (d) sodium at a concentration of about 130.0 to 140.0 mM/l, (e) chloride at a concentration of about 118.0 to 136.5 mM/l, (f) calcium at a concentration of about 0.5 to 2.0 mM/l, (g) magnesium at a concentration of about 0.3 to 1.1 mM/l, and (e) phosphate at a concentration of about 0.8 to 2.2 mM/l. Preferred concentrations of these components range from 0.25% to 1.50% for tetracycline, 23.0 to 42.0 mM/l potassium, 31.0 to 48.0 mM/l bicarbonate, 131.0 to

139.0 mM/l sodium, 124.0 to 136.0 mM/l chloride, 0.6 to 0.8 mM/l calcium, 0.5 to 0.6 mM/l magnesium, and 1.0 to 2.0 mM/l phosphate.

In a particularly preferred embodiment, the ophthalmic solution is made up of a tetracycline compound present in Solution 15 containing the following components:

- 5 99.0 mmol/l NaCl; 24.0 mmol/l KCl; 0.8 mmol/l CaCl₂; 0.6 mmol/l MgCl₂; 32 mmol/l NaHCO₃; 1.0 mmol/l NaH₂PO₄ at an osmolality (mOsm/kg) 302.

- The pH of the ophthalmic preparation generally ranges from about 7.0 to 8.0, as measured by, for example, a Fisher pH Accumet Model 600. However, this pH range need not be rigidly adhered to, and it may be desirable to alter pH outside of this range, for instance, to improve ophthalmic drug penetration through the ocular surface. In view of the teachings provided herein, those skilled in the art may employ other pH ranges.

- In preferred embodiments, the ophthalmic preparation is isotonic. However, the final osmolality may be adjusted according to conditions present in the tear film or on the ocular surface (e.g., tear film osmolality). For example, treatment of hypertonic tear films may make diluted preparations preferable. Conversely, preparations may be concentrated to hypertonic concentrations if therapeutically desirable. It is known that hypotonic and hypertonic eyedrops are brought rapidly to isotonicity by movement of water across the eye surface (Maurice et al. (1971) Exp. Eye Res. 11:30). Thus, when treating elevated tear film osmolality (as associated, for example, with dry eye disorders), it may be preferable to dilute the ophthalmic preparation to hypotonicity while maintaining the proportions or balance of the electrolytes disclosed herein, and adjusting the concentration of the tetracycline compound such that the appropriate concentration is attained after entrance of water from the solution into the eye surface.

- Ophthalmic preparations of the invention can be applied to the ocular surface by various methods known in the art. For example, the preparation can be topically to the ocular surface as eye drops. The preparation can also be applied using an eye cup so that the eye is bathed. The preparation can also be applied using a continuous or near continuous infusion device for ocular surface irrigation and/or wetting and/or drug delivery. The preparation may also be applied by devices that spray solutions as required onto the surface of the eye.

The invention shall be further described in the following working examples:

EXAMPLES

35 Animals

Male and female New Zealand white rabbits weighing between 2.5 and 3.5 kg were anesthetized with ketamine (100 mg/kg) and xylazine (10 mg/kg). Meibomian

gland duct orifices were closed by cautery in the right eyes of all rabbits as previously described (7).

Treatment Groups

Four treatment groups (groups I, II, III, IV and V) were designated, each containing four rabbits: group I received no treatment; group II received tetracycline hydrochloride (Sigma Chemical, St. Louis, Mo.) intramuscularly at a dosage of 50 mg/kg/d (given as a solution of 500 mg/ml in sterile saline for injection USP) for five days each week; group III received tetracycline hydrochloride 1% in plastibase 50W and light mineral oil eyedrops (Achromycin, Lederle, Pearl River, N.Y.) four times a day for five days each week; and group IV received tetracycline hydrochloride 1% (Sigma Chemical, St. Louis, Mo.) in Solution 15-electrolyte vehicle (23) four times a day for five days each week. Solution 15 contains 99.0 mmol/l NaCl; 24.0 mmol/l KCl; 0.8 mmol/l CaCl₂; 0.6 mmol/l MgCl₂; 32 mmol/l NaHCO₃; 1.0 mmol/l NaH₂PO₄ at an osmolality (mOsm/kg) of 302. Treatments began at 8 weeks post-op and continued until 20 weeks.

Treatment Evaluation

All rabbits were sacrificed at 20 weeks postoperatively by overdose with pentobarbital. At the time of death corneal epithelium was removed for measurement of corneal epithelial glycogen level as previously described (25). Conjunctival biopsies were then taken for counting of goblet cell density as previously described (10). Lower eyelids were then removed by sharp dissection and placed in one-half strength Karnovsky's fixative. The tissue was then dehydrated through graded alcohols and embedded in methacrylate. Three μ M sections were cut through the eyelids horizontally for light microscopy, and stained with alkaline giemsa.

Leukocytes were quantified in tissue sections using a method similar to that described by Sherwood et al. (26). For descriptive purposes, eyelid tissue was divided into three zones: 1) tarsal conjunctival epithelium, 2) underlying stroma, and 3) meibomian glands and adjacent tissue, including tarsal plate. Two separate sections, separated by a distance sufficient to provide two separate inflammatory cell populations, were examined for each eyelid. At a magnification of 40X, nine consecutive fields were counted for each zone in each section yielding a total of 18 fields per zone per eyelid. Leukocytes were identified as either neutrophils, eosinophils, basophils, or mastcells.

Quantification of corneal glycogen, conjunctival goblet-cell density, and leukocytes was performed in a masked fashion. Corneal glycogen and conjunctival-goblet cell density was calculated as a percent of contralateral unoperated/untreated control eyes. Leukocytes were calculated as a mean per 40X field. Groups were compared using a pooled estimate of variance (Microstat, Microsoft Corporation).

Results

Twenty weeks after meibomian gland orifice closure, untreated rabbits had a significant increase in eyelid tissue mast cells, eosinophils, neutrophils and basophils (P<0.05) relative to unoperated controls. Mast cells were not seen in the conjunctival epithelium of normal eyes nor after meibomian gland orifice closure. With this exception, all leukocyte types increased in all three tissue zones studied (Figures 1-3).

After 12 weeks of treatment, all rabbits treated with either systemic or topical tetracycline, in either vehicle, demonstrated a significant decrease in all leukocyte types in the conjunctival epithelium and meibomian gland/eye lid-zones (P<0.05). In the conjunctival stroma zone all rabbits treated with either systemic or topical tetracycline showed a significant decrease in mast cells, neutrophils, and basophils (P<0.05). Tetracycline in Solution 15 significantly decreased eosinophils in the stroma zone (P<0.05), whereas the decreases seen with the other tetracycline treatments did not attain statistical significance (Figures 1-3).

Goblet-cell density in rabbits 20 weeks after meibomian gland orifice closure had decreased to $84.5\% \pm 0.5$ of contralateral normal controls ($p<0.05$). Treatment with systemic tetracycline had no effect on conjunctival goblet-cell density, while topical treatment with Achromycin significantly decreased goblet-cell density ($80.1\% \pm 0.7$, $P<0.005$). Topical treatment with tetracycline in Solubon 15 significantly restored conjunctival goblet cells ($90.4\% \pm 2.2$, $P<0.05$) (Figure 4).

Corneal epithelial glycogen in rabbits 20 weeks after meibomian gland orifice closure had decreased to $78.7\% \pm 0.8$ of contralateral controls ($p<0.05$). Treatment with systemic tetracycline had no effect on corneal glycogen, while topical treatment with Achromycin significantly decreased corneal glycogen ($75.3\% \pm 0.3$, $P<0.01$). Topical treatment with tetracycline in Solution 15 significantly restored corneal glycogen ($83.7\% \pm 0.9$, $P<0.005$) (Figure 5).

Discussion

The present study demonstrates that systemic and topically administered tetracycline decreases the concentration of inflammatory cells in the eyelid and eye surface tissue of a rabbit model for meibomianitis and meibomian gland dysfunction. However, relatively low-dose topically applied tetracycline in the Solution 15 vehicle was more effective than relatively high-dose systemic tetracycline or topically applied Achromycin, and was the only treatment effective in restoring conjunctival goblet cells and corneal glycogen.

It has previously been shown that bacterial pathogens remain on the eyelids of patients successfully treated with tetracycline (2), that tetracycline does not affect the composition of meibomian gland secretions in meibomianitis (27), and that tetracycline levels are unlikely to be adequate to inhibit bacterial lipase activity (28). These data support the conclusion that the effectiveness of tetracycline in the treatment of meibomianitis is secondary to its ability to decrease inflammation.

The findings of the present studies also are consistent with those of Seedor et al. (29), who have demonstrated that systemically administered tetracycline decreases inflammatory cells in the corneal stroma of rabbits with corneal alkali burns.

A prominent feature of acne rosacea is the presence of inflammatory cells in the upper and middermis (30). The studies described herein suggest that the effectiveness of tetracycline in the treatment of acne rosacea dermatitis is due its ability to decrease tissue leukocytes. Topical steroids also decrease inflammation and have been used to treat meibomianitis. Unlike steroids, however, tetracyclines do not have the potential to increase intraocular pressure or to promote cataract formation.

Currently, tetracycline is generally administered systemically to patients to treat meibomianitis (5), or topically in oil-based preparations. While systemic tetracycline decreased tissue leukocytes in the current study, it did not improve conjunctival goblet-cell density or corneal glycogen. The topically administered commercial tetracycline tested in the current study significantly exacerbated the loss of goblet-cells and corneal glycogen seen with the dry-eye surface disease resulting from meibomian gland dysfunction. An ophthalmic preparation containing tetracycline in Solution 15, however, was able to decrease tissue leukocytes while simultaneously restoring conjunctival goblet-cell density and corneal glycogen in the currently disclosed rabbit model for meibomianitis and meibomian gland dysfunction. In addition, this ophthalmic preparation has the advantage of being a local rather than systemic therapy.

In conclusion, the results of the studies described herein suggest that topically applied ophthalmic preparations containing tetracycline in aqueous solution can be used clinically to treat meibomianitis and the dry eye surface disease resulting from meibomian gland dysfunction more effectively than either systemic tetracycline or commercial oil-based topical tetracycline. These ophthalmic preparations also may serve to treat other inflammatory ocular surface diseases and their complications.

EQUIVALENTS

Although the invention has been described with reference to its preferred embodiments, other embodiments can achieve the same results. Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation,

numerous equivalents to the specific embodiments described herein. Such equivalents are considered to be within the scope of this invention and are encompassed by the following claims.

5

INCORPORATION BY REFERENCE

All references and patents cited herein are hereby incorporated by reference in their entirety.

10 REFERENCES

1. Jenkins MS, Brown SI, Lempert SL, Weinberg RJ. Ocular rosacea. Am. J. Ophthalmol. 1979; 88:618-622.
2. Brown SI, Shahinian L. Diagnosis and treatment of ocular rosacea. Ophthalmol.
15 1978; 85:779-786.
3. Bartholomew B, Reid BJ, Cheesbrough MJ, MacDonald M, Galloway NR. Oxytetracycline in the treatment of ocular rosacea: a double-blind trial. Br. J. Ophthalmol. 1982; 66:386-388.
- 20 4. McCulley JP Blepharoconjunctivitis. Int. Ophthalmol Clin. 1984; 24:65-77.
5. McCulley JP, Dougherty JM. Blepharitis associated with acne rosacea and seborrheic dermatitis. Int Ophthalmol Clin. 1985;25:159-172.
- 25 6. Bowman RW, Miller KN, McCulley JP. Diagnosis and treatment of chronic blepharitis. In Wagner MD ed. Volume VII Module 10, Focal Points 1989: Clinical Modules for Ophthalmologists. San Francisco, American Academy of Ophthalmology, 1989.
- 30 7. Gilbard JP, Rossi SR, Gray Heyda K. Tear film and ocular surface changes after meibomian gland orifice closure in the rabbit. Ophthalmology. 1989; 96:1180-1186.
8. Gutgesell VJ, Stern GA, Hood CI. Histopathology of meibomian gland dysfunction.
35 Am J Ophthalmol. 1982; 94:383-387.

9. Robin JB, Jester JV, Nobe J, et al. In vivo transillumination biomicroscopy and photography of meibomian gland dysfunction: a clinical study. *Ophthalmology* 1985; 92:1423-1426.
- 5 10. Gilbard, JP, Rossi SR, Gray KL. A new rabbit model for keratoconjunctivitis sicca. *Invest Ophthalmol Vis Sci*. 1987; 28:225-228.
11. Gilbard, JP, Rossi SR, Gray KL, Hanninen LA, Kenyon KR. Tear film osmolarity and ocular surface disease in two rabbit models for keratoconjunctivitis sicca. *Invest*
10 *Ophthalmol Vis Sci*. 1988; 29:374-378.
12. Mathers WD. Ocular evaporation in meibomian gland dysfunction and dry eye. *Ophthalmology*. 1993; 100:347-351.
- 15 13. Hoeprich PD, Warshauer DM. Entry of tetracyclines into saliva and tears. *Antimicrob Agents Chemother*. 1974; 5:330-336.
14. Dilly PN, Mackie IA. Distribution of tetracycline in the conjunctiva of patients on long term systemic doses. *Br J Ophthalmol*. 1985; 69:25-28.
- 20 15. Golub LM, Lee HM, Lehrer G, Nemiroff A, McNamara TF, Kaplan R, Ramamurthy NS. Minocycline reduces gingival collagenolytic activity during diabetes. Preliminary observations and a proposed new mechanism of action. *J Periodont Res*. 1983; 18:516-526.
- 25 16. Golub LM, Ramamurthy N, McNamara TF, Gomes B, Wolff M, Casino A, Kapoor A, Zambon J, Ciancio S, Schneir M, Perry H. Tetracyclines inhibit tissue collagenase activity. A new mechanism in the treatment of periodontal disease. *J Periodont Res*. 1984; 19:651-655.
- 30 17. Golub LM, Wolff M, Lee HM, McNamara TF, Ramamurthy NS, Zambon J, Ciancio S. Further evidence that tetracyclines inhibit collagenase activity in human crevicular fluid and from other mammalian sources. *J Periodont Res*. 1985; 20:12-23.
- 35 18. Martin RR, Warr GA, Couch RB, Yeager H, Knight V. Effects of tetracycline on leukotaxis. *J Infect Dis*. 1974; 129:110-116.

19. Belsheim J, Gnarpe H, Persson S. Tetracyclines and host defense mechanisms: interference with leukocyte chemotaxis. *Scand J Infect Dis.* 1979; 11:141-145.
20. Esterly NB, Koransky JS, Furey NL, Trevisan M. Neutrophil chemotaxis in
5 patients with acne receiving oral tetracycline therapy. *Arch Dermatol.* 1984; 120:1308-1313.
21. Elewski BE, Lamb BAJ, Sams WM, Gammon WR. In vivo suppression of neutrophil chemotaxis by systematically and topically administered tetracycline. *J Am*
10 *Acad Dermatol.* 1983; 8:807-812.
22. Forsgren A, Schmeling D, Quie PG. Effect of tetracycline on the phagocytic function of human leukocytes. *J Infect Dis.* 1974; 130:412-415.
- 15 23. Gilbard JP, Rossi SR, Gray Heyda K. Ophthalmic solutions, the ocular surface, and a unique therapeutic artificial tear formulation. *Am J Ophthalmol.* 1989; 107:348-355.
24. Gilbard JP, Rossi SR. An electrolyte-based solution that increases corneal glycogen and conjunctival goblet cell density in a rabbit model for keratoconjunctivitis sicca.
20 *Ophthalmology.* 1992; 99:600-604.
25. Friend J, Kiorpes T, Kinoshita S. Glycogen and DNA content of corneal epithelium: Comparison of preparation methods. *Invest Ophthalmol Vis Sci.* 1983; 24:203-207.
26. Sherwood MB, Grierson I, Millar L, Hitchings RA. Long-term morphologic effects of antiglaucoma drugs on the conjunctiva and tenon's capsule in glaucomatous patients. *Ophthalmology.* 1989; 96:327-335.
- 30 27. Nicolaides N, Santos EC, Smith RE: Meibum lipids in rosacea, blepharitis, and chalazia. *Inves Ophthalmol Vis Sci* 1983; 24(suppl): 78.
28. Salamon SM. Tetracyclines in ophthalmology. *Surv Ophthalmol.* 1985; 29:265-275.
35

29. Seedor JA, Perry HD, McNamara TF, Golub LM, Buxton DF, Guthrie DS. Systemic tetracycline treatment of alkali-induced corneal ulceration in rabbits. Arch Ophthalmol. 1987; 105:268-271.
- 5 30. Marks R, Harcourt-Webster JN. Histopathology of rosacea. Arch. Derm. 1969; 100:683-691.

What is claimed is:

1. An ophthalmic preparation for topical application to the eye, the preparation comprising an aqueous solution containing (a) a tetracycline compound in
5 an amount sufficient to treat an ocular disease characterized by eye surface inflammation; and (b) a balance of electrolytes selected from the group consisting of potassium, chloride, bicarbonate and sodium,
wherein said potassium is present at a concentration of about 22.0 to 43.0 mM/l, said bicarbonate is present at a concentration of about 29.0 to 50.0 mM/l, said sodium is
10 present at a concentration of about 130.0 to 140.0 mM/l, and said chloride is present at a concentration of about 118.0 to 136.5 mM/l, or a therapeutically effective dilution or concentration of said solution.
2. The ophthalmic preparation of claim 1 wherein said solution has an
15 osmolarity of about 296-325 mOsm/Kg.
3. The ophthalmic preparation of claim 1, wherein said solution further comprises a balance of electrolytes selected from the group consisting of calcium, magnesium and phosphate, wherein said calcium is present at a concentration of about
20 0.5 to 2.0 mM/l, said magnesium is present at a concentration of about 0.3 to 1.1 mM/l, and said phosphate is present at a concentration of about 0.8 to 2.2 mM/l.
4. The ophthalmic preparation of claim 3 wherein said solution has an
25 osmolarity of about 296-325 mOsm/Kg.
5. The ophthalmic preparation of claim 1 wherein said tetracycline compound is tetracycline hydrochloride.
6. The ophthalmic preparation of claim 1 wherein said tetracycline
30 compound is tetracycline hydrochloride present at a concentration of about 0.125% to 2% when the solution is isotonic or attains isotonicity.
7. An ophthalmic solution comprising:
(a) a tetracycline compound at a concentration equivalent in anti-
35 inflammatory potency to tetracycline at a concentration of about 0.125% to 2% when the solution is isotonic or attains isotonicity;
(b) potassium at a concentration of about 22.0 to 43.0 mM/l;

- 17 -

- (c) bicarbonate at a concentration of about 29.0 to 50.0 mM/l;
- (d) sodium at a concentration of about 130.0 to 140.0 mM/l, and
- (e) chloride at a concentration of about 118.0 to 136.5 mM/l,

or a therapeutically effective dilution or concentration of said solution.

5

8. The ophthalmic solution of claim 7 wherein said solution has an osmolarity of about 296-325 mOsm/Kg.

9. The ophthalmic solution of claim 7 further comprising:

10

- (a) calcium at a concentration of about 0.5 to 2.0 mM/l,
- (b) magnesium at a concentration of about 0.3 to 1.1 mM/l, and
- (c) phosphate at a concentration of about 0.8 to 2.2 mM/l.

10. The ophthalmic solution of claim 9 wherein said solution has an osmolarity of about 296-325 mOsm/Kg.

15

11. A method of treating eye surface inflammation or dryness comprising topically applying to the surface of an eye of a subject suffering from said disorder an ophthalmic solution comprising: (a) a tetracycline compound in an amount sufficient to treat an ocular disease characterized by eye surface inflammation; and (b) a balance of electrolytes selected from the group consisting of potassium, chloride, bicarbonate and sodium, wherein said potassium is present at a concentration of about 22.0 to 43.0 mM/l, said bicarbonate is present at a concentration of about 29.0 to 50.0 mM/l, said sodium is present at a concentration of about 130.0 to 140.0 mM/l, and said chloride is present at a concentration of about 118.0 to 136.5 mM/l, or a therapeutically effective dilution of said solution.

20

25

12. The method of claim 11 wherein said solution has an osmolarity of about 296-325 mOsm/Kg.

30

13. The method of claim 11 wherein said tetracycline compound is tetracycline hydrochloride at a concentration of about 0.125% to 2% when the solution is isotonic or attains isotonicity.

35

14. A method of simultaneously reducing inflammation and dryness of an ocular surface, comprising topically applying to said ocular surface an ophthalmic solution comprising: (a) a tetracycline compound in an amount sufficient to treat an

- 18 -

ocular disease characterized by eye surface inflammation; and (b) a balance of electrolytes selected from the group consisting of potassium, chloride, bicarbonate and sodium, wherein said potassium is present at a concentration of about 22.0 to 43.0 mM/l, said bicarbonate is present at a concentration of about 29.0 to 50.0 mM/l, said sodium is
5 present at a concentration of about 130.0 to 140.0 mM/l, and said chloride is present at a concentration of about 118.0 to 136.5 mM/l, or a therapeutically effective dilution of said solution.

15. An ophthalmic preparation comprising an aqueous solution containing
10 one or more tetracycline compounds in an amount sufficient to treat an ocular disease characterized by eye surface inflammation.


16. The ophthalmic preparation of claim 15 wherein said tetracycline compound is tetracycline hydrochloride.

15



17. The ophthalmic preparation of claim 16 wherein said tetracycline hydrochloride is present at a concentration of about 0.125% to 2% when the solution is isotonic or attains isotonicity.

20

1/4

*FIG. 1*

2/4



EFFECT OF VARIOUS TETRACYCLINE TREATMENTS ON CONJUNCTIVAL
GOBLET-CELL DENSITY IN A RABBIT MODEL FOR MEIBOMITIS/
MEIBOMIAN GLAND DYSFUNCTION




FIG. 4

4/4




FIG. 5

INTERNATIONAL SEARCH REPORT

In. tional Application No

PCT/US 99/17185

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/65

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E	WO 99 58131 A (UNIVERSITY OF MIAMI, USA) 18 November 1999 (1999-11-18) page 9, line 5-10; claims 1,2,5,23-25,27; examples 5,6	1-17
Y	JP 62 240629 A (KAO CORP) 21 October 1987 (1987-10-21) abstract	1-17
Y	EP 0 205 279 A (RETINA FOUND EYE RES INST) 17 December 1986 (1986-12-17) abstract; claims 1,2,4-7; table 2	1-17
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

° Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

12 January 2000

Date of mailing of the international search report

26/01/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Gonzalez Ramon, N

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/17185

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y,P	SCOTT C. A: ET AL: "Optometric clinical practice guideline care of the patient with ocular surface disease" OCULAR SURFACE DISEASE, 'Online! 5 June 1999 (1999-06-05), pages 1-33, XP002127393 Retrieved from the Internet: <URL:www.aoanet.org/cpg-10-cposd.html> 'retrieved on 2000-01-07! page 20	1-17
X	--- VAN GOGH E.R. ET AL: "' Topical antibiotics in ophthalmology. A review!. TOEPASSING VAN ANTIMICROBIELE MIDDELEN IN HET OOG IN DE EERSTELIJNS GEZONDHEIDSZORG. EEN OVERZICHT." PHARMACEUTISCH WEEKBLAD, (1994) 129/6-7 (156-163). , XP000866302 table 5	1-17
Y	--- SALAMON S M: "Tetracyclines in ophthalmology." SURVEY OF OPHTHALMOLOGY, (1985 JAN-FEB) 29 (4) 265-75. REF: 100 , XP000866303 page 272	1-17
X	--- HUBER-SPITZY V ET AL: "'Treatment of Ocular Chlamydial Infection: Comparison of Tetracyclines and Norfloxacin!. Behandlung der okularen Chlamydieninfektion: Tetracycline und Norfloxacin im Vergleich." OPHTHALMOLOGICA, (1992) 205 (2) 64-8. , XP000866288 abstract -----	1-17

INTERNATIONAL SEARCH REPORT

Information on patent family members

In ternational Application No

PCT/US 99/17185

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9958131	A	18-11-1999	NONE	
JP 62240629	A	21-10-1987	NONE	
EP 0205279	A	17-12-1986	AT 68700 T	15-11-1991
			CA 1263606 A	05-12-1989
			DE 3682117 A	28-11-1991
			JP 7108856 B	22-11-1995
			JP 62026225 A	04-02-1987
			US 4911933 A	27-03-1990
			US 4775531 A	04-10-1988